398 related articles for article (PubMed ID: 27015560)
1. mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.
Chen Y; Qian J; He Q; Zhao H; Toral-Barza L; Shi C; Zhang X; Wu J; Yu K
Oncotarget; 2016 May; 7(18):25224-40. PubMed ID: 27015560
[TBL] [Abstract][Full Text] [Related]
2. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
3. mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis.
Martinez Calejman C; Trefely S; Entwisle SW; Luciano A; Jung SM; Hsiao W; Torres A; Hung CM; Li H; Snyder NW; Villén J; Wellen KE; Guertin DA
Nat Commun; 2020 Jan; 11(1):575. PubMed ID: 31996678
[TBL] [Abstract][Full Text] [Related]
4. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
6. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
Li S; Oh YT; Yue P; Khuri FR; Sun SY
Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
[TBL] [Abstract][Full Text] [Related]
8. ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury.
Chen Y; Deb DK; Fu X; Yi B; Liang Y; Du J; He L; Li YC
FASEB J; 2019 Aug; 33(8):9602-9615. PubMed ID: 31150280
[TBL] [Abstract][Full Text] [Related]
9. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Role of ATP-Citrate Lyase in the Immune System.
Dominguez M; Brüne B; Namgaladze D
Front Immunol; 2021; 12():632526. PubMed ID: 33679780
[TBL] [Abstract][Full Text] [Related]
11. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
12. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
13. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
14. ACSS2-mediated acetyl-CoA synthesis from acetate is necessary for human cytomegalovirus infection.
Vysochan A; Sengupta A; Weljie AM; Alwine JC; Yu Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1528-E1535. PubMed ID: 28167750
[TBL] [Abstract][Full Text] [Related]
15. ATP citrate lyase inhibitors as novel cancer therapeutic agents.
Zu XY; Zhang QH; Liu JH; Cao RX; Zhong J; Yi GH; Quan ZH; Pizzorno G
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):154-67. PubMed ID: 22339355
[TBL] [Abstract][Full Text] [Related]
16. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
17. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
18. ATP-citrate lyase is essential for high glucose-induced histone hyperacetylation and fibrogenic gene upregulation in mesangial cells.
Deb DK; Chen Y; Sun J; Wang Y; Li YC
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F423-F429. PubMed ID: 28490526
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of cytosolic acetyl-CoA generation.
Fatland B; Anderson M; Nikolau BJ; Wurtele ES
Biochem Soc Trans; 2000 Dec; 28(6):593-5. PubMed ID: 11171137
[TBL] [Abstract][Full Text] [Related]
20. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
